Rein Therapeutics Inc. has announced a collaboration with Qureight Ltd to integrate deep-learning technology into their upcoming Phase 2 clinical trial of LTI-03, aimed at treating idiopathic pulmonary fibrosis $(IPF.UK)$. This partnership will leverage Qureight's advanced AI imaging platform to provide detailed insights into the effects of LTI-03 on lung structure and function. The Phase 2 trial will assess the safety, tolerability, and activity of LTI-03 across multiple biomarkers, as well as its potential for promoting healthy tissue regeneration. Rein Therapeutics previously reported positive results from their Phase 1b trial, showing promising trends in biomarker response. Further details about the Phase 2 trial design are expected to be announced soon.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.